Immuno-Oncology Synergy Pepinemab blocks SEMA4D to promote immune infiltration and boost responses to immunotherapies in solid tumors. This creates opportunities to co-develop or license combination regimens with checkpoint inhibitors in head and neck cancer and melanoma.

Neurodegenerative Partnerships Vaccinex is advancing Alzheimer's disease and Huntington's disease programs by targeting neuroinflammation and astrogliosis. Positioning for strategic collaborations with large pharma or biotech focused on neurodegeneration could accelerate late-stage development and broaden reach.

ActivMAb Platform ActivMAb is a proprietary antibody discovery platform for high value targets on multi-pass membrane receptors. There is potential to monetize via licensing deals and multi-project collaborations with firms seeking novel antibody modalities.

Strategic Financing The company has pursued partnerships and alternative financing and has delisted from Nasdaq, signaling a lean capital approach. This suggests openness to strategic alliances, licensing arrangements, or funding partnerships to advance key programs.

Outsourcing & Partnerships A small team with active clinical programs points to strong fit for outsourcing to CROs and CDMOs for trial execution and manufacturing. Focus areas include co-development opportunities, regulatory support partnerships, and supply agreements to accelerate timelines.